Search by Drug Name or NDC
NDC 42582-0800-08 Sodium Sulfacetamide and Sulfur Cleanser 100; 20 mg/g; mg/g Details
Sodium Sulfacetamide and Sulfur Cleanser 100; 20 mg/g; mg/g
Sodium Sulfacetamide and Sulfur Cleanser is a TOPICAL CREAM in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bi-Coastal Pharma International LLC. The primary component is SULFACETAMIDE SODIUM; SULFUR.
Product Information
| NDC | 42582-0800 |
|---|---|
| Product ID | 42582-800_1105962f-1a95-44ef-9e69-d61f5a501eb7 |
| Associated GPIs | 90059903200918 |
| GCN Sequence Number | 066048 |
| GCN Sequence Number Description | sulfacetamide sodium/sulfur CLEANSER 10 %-2 % TOPICAL |
| HIC3 | Q5S |
| HIC3 Description | TOPICAL SULFONAMIDES |
| GCN | 28226 |
| HICL Sequence Number | 003344 |
| HICL Sequence Number Description | SULFACETAMIDE SODIUM/SULFUR |
| Brand/Generic | Generic |
| Proprietary Name | Sodium Sulfacetamide and Sulfur Cleanser |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | SULFACETAMIDE SODIUM and SULFUR |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CREAM |
| Route | TOPICAL |
| Active Ingredient Strength | 100; 20 |
| Active Ingredient Units | mg/g; mg/g |
| Substance Name | SULFACETAMIDE SODIUM; SULFUR |
| Labeler Name | Bi-Coastal Pharma International LLC |
| Pharmaceutical Class | Sulfonamide Antibacterial [EPC], Sulfonamides [CS] |
| DEA Schedule | n/a |
| Marketing Category | UNAPPROVED DRUG OTHER |
| Application Number | n/a |
| Listing Certified Through | 2023-12-31 |
Package
Package Images
NDC 42582-0800-08 (42582080008)
| NDC Package Code | 42582-800-08 |
|---|---|
| Billing NDC | 42582080008 |
| Package | 227 g in 1 BOTTLE (42582-800-08) |
| Marketing Start Date | 2011-06-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL 1aa63fb0-05d9-426a-aa45-264373a23d9f Details
DESCRIPTION
Each gram of Sodium Sulfacetamide and Sulfur (sodium sulfacetamide 10% w/w and sulfur 2% w/w) contains 100 mg of sodium sulfacetamide and 20 mg of colloidal sulfur in a vehicle consisting of: aloe barbadensis (aloe vera) leaf extract, butylated hydroxytoluene, camellia oleifera (green tea) leaf extract, cetyl alcohol, disodium oleamido MEA sulfosuccinate, edetate disodium, fragrance, glycerin, glyceryl monostearate, magnesium aluminum silicate, methylparaben, PEG-100 stearate, propylparaben, purified water, sodium cocoyl isethionate, sodium methyl cocoyl taurate, sodium thiosulfate, stearyl alcohol, xantham gum.
Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Sodium sulfacetamide is C8H9N2NaO3S∙H2O with molecular weight of 254.24. Chemically, it is N-[(4-aminophenyl)sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:
CLINICAL PHARMACOLOGY
The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours.
The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.
INDICATIONS
CONTRAINDICATIONS
WARNINGS
Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.
Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF REACH OF CHILDREN.
PRECAUTIONS
FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.
General
If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.
Carcinogenesis, Mutagenesis and Impairment of Fertility
Long-term studies in animals have not been performed to evaluate carcinogenic potential.
Pregnancy
Category C
Animal reproduction studies have not been conducted with Sodium Sulfacetamide 10% and Sulfur 2% Cleanser. It is also not known whether Sodium Sulfacetamide 10% and Sulfur 2% Cleanser can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 10% and Sulfur 2% Cleanser should be given to a pregnant woman only if clearly needed.
Nursing Mothers
It is not known whether sodium sulfacetamide is excreted in human milk following topicaI use of Sodium Sulfacetamide 10% and Sulfur 2% Cleanser. However, small amounts of orally administered sulfonamides have been reported to be excreted in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide 10% and Sulfur 2% Cleanser is administered to a nursing woman.
ADVERSE REACTIONS
DOSAGE AND ADMINISTRATION
Wash affected areas with Sodium Sulfacetamide 10% and Sulfur 2% Cleanser one to two times daily, or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10 to 20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using cleanser less often.
HOW SUPPLIED
Sodium Sulfacetamide 10% and Sulfur 2% Cleanser is supplied in an 8 oz. (227 g) bottle, NDC 42582-800-08.
Store at 25°C (77°F); excursions permitted to between 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature.
Note: Protect from freezing and excessive heat. The product may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product. Keep tube or packet tightly closed.
Occasionally, a slight yellowish discoloration may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration, however, presents no problem, as it is readily removed by ordinary laundering without bleaches.
SPL UNCLASSIFIED SECTION
PRINCIPAL DISPLAY PANEL - 227 g Bottle Label
INGREDIENTS AND APPEARANCE
| SODIUM SULFACETAMIDE AND SULFUR CLEANSER
sulfacetamide sodium and sulfur cream |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Labeler - Bi-Coastal Pharma International LLC (078397428) |
| Registrant - Bi-Coastal Pharma International LLC (078397428) |